Resting Energy Expenditure in Patients With Cystic Fibrosis: A Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03699982|
Recruitment Status : Recruiting
First Posted : October 9, 2018
Last Update Posted : May 21, 2019
Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. Individuals with cystic fibrosis often have poor weight gain and growth that can negatively impact health further by worsening lung function. Additionally, persons with the disease typically need more than the usual calories on a daily basis.
Most institutions estimate these patients' caloric needs using weight, age, and sex based mathematical formulae. However, numerous studies show that use of these formulae often yields inaccurate caloric values. Use of indirect calorimetry may give more accurate estimates of caloric needs in patients with cystic fibrosis.
The aim of our study is to assess the accuracy of caloric estimates generated using one such widely used mathematical formula, the Harris-Benedict equation, and to compare this calorie value with that obtained from indirect calorimetry testing in pediatric and adult patients with cystic fibrosis.
Study investigators will use the newly calculated caloric requirements in dietary counseling. Changes in weight and lung function after 3 months will be compared to participants' historical changes.
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis||Other: Daily calorie target based on resting energy expenditure||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Resting Energy Expenditure in Patients With Cystic Fibrosis: A Pilot Study|
|Actual Study Start Date :||October 10, 2018|
|Estimated Primary Completion Date :||October 8, 2019|
|Estimated Study Completion Date :||October 8, 2019|
Experimental: Cystic fibrosis patients
Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
Other: Daily calorie target based on resting energy expenditure
Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.
Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake.
- Resting energy expenditure estimation [ Time Frame: 1 hour ]Resting energy expenditure will be obtained using indirect calorimetry and the Harris-Benedict Equation.
- Morphological variable changes [ Time Frame: 3 months ]Weight/height/BMI changes after 3 months of intervention and historical weight/height/BMI changes occurring during the 12 preceding months (reported as 3 month means).
- Changes in pulmonary function status [ Time Frame: 3 months ]Changes in pulmonary function status, including FEV1%, after 3 months of intervention and historical pulmonary function status changes occurring during the 12 preceding months (reported as 3 month means).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03699982
|Contact: Amanda Dye, MDfirstname.lastname@example.org|
|United States, West Virginia|
|CAMC - Women and Children's Hospital||Recruiting|
|Charleston, West Virginia, United States, 25302|
|Principal Investigator:||Amanda Dye, MD||CAMC and WVU-Charleston|